Autoinflammatory & rare systemic diseases
Thalidomide can effectively prevent relapse in IgG4-related disease outweighing its side effects: a multicentre, randomised, double-blinded, placebo-controlled study
Authors' conclusion
Thalidomide can effectively prevent relapse in IgG4-RD outweighing its side effects
Study context
- Population
- Patients with active IgG4-related disease (IgG4-RD)57 finished per protocol
- Participants
- 60 patients
- Comparison
- Glucocorticoids (GCs)+Thalidomide vs GCs+Placebo
- GCs+Thalidomiden = 29
- GCs+Placebon = 28reference
- Primary endpoint
- Disease relapse rate
- Follow-up
- Month 12
Methodological detailsmulticentre, double-blinded, placebo-controlled, 1:1 randomisation
- Multicentre
- Double-blinded
- Placebo-controlled
- 1:1 randomisation
Primary result
As reported in the abstract
Relapse rate
- NNT for thalidomide (relapse)
- 2
Secondary outcomes
Remission rate · month 12
Response rate
Safety
Adverse events (AEs) (all participants) · 12-month follow-up
- Total AEs
- 49
- Participants with AEs
- 35
- Moderate AEs
- 4
- Mild AEs
- 45
- NNH for thalidomide (moderate AEs)
- 8
Original publication
Thalidomide can effectively prevent relapse in IgG4-related disease outweighing its side effects: a multicentre, randomised, double-blinded, placebo-controlled study. Ann Rheum Dis. Published 16 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →